Involvement of the Serotonergic System in the Control of Impulsivity in Tourette Disorder.
Overview
- Phase
- Phase 2
- Intervention
- Administration of a PET radiotracer
- Conditions
- Tourette Disorder
- Sponsor
- Hospices Civils de Lyon
- Enrollment
- 25
- Locations
- 2
- Primary Endpoint
- Correlation coefficients between receptor-specific imaging data (PET) and scores of impulsivity measured by the Barratt scale (BIS11).
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
Tourette disorder (TD) is a neurodevelopmental disorder characterized by motor and vocal tics. It is often associated with multiple psychiatric comorbidities involving a high degree of impulsivity such as obsessive-compulsive disorders (OCD), attention-deficit hyperactivity disorders (ADHD), and intermittent explosive disorders (IED). Although a substantial body of clinical studies have emphasized the role of the dopamine system in motor symptoms, little is known about how the serotonergic (5-HT) system modulate both cognitive and affective abilities in TD. Several lines of evidence suggest that different 5-HT receptor subtypes may constitute a crucial factor in the development and maintenance of different symptoms. Because abnormal 5-HT2A receptor bindings have been reported in patients with TD and aripiprazole (drug of first choice) is a 5-HT2A antagonist, we hypothesize that 5-HT2A receptors may play an important role in regulating psychiatric symptoms in TD such as those characterized by impulsive behaviors. To investigate the involvement of 5-HT2A receptors in TD, we propose to perform a multimodal imaging study with 20 adult patients (ON and OFF treatment). Neuroimaging data will be collected with a hybrid system that simultaneously combines the positron emission tomography (PET) and the functional magnetic resonance imaging (fMRI). A highly selective PET radiotracer ([18F]-altanserin) will map 5-HT2A receptor bindings in the whole brain, while fMRI will provide detail information regarding the altered brain activities.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
Tourette disorder
25 mixt adult patients with TD. Patients will be recruited if a current treatment by aripiprazole (5-15 mg) is already scheduled before the study.
Intervention: Administration of a PET radiotracer
Outcomes
Primary Outcomes
Correlation coefficients between receptor-specific imaging data (PET) and scores of impulsivity measured by the Barratt scale (BIS11).
Time Frame: As the analysis requires a complex imaging processing, this outcome measure will be assessed in the year following the acquisition.
Correlation coefficients between changes in the binding potential (BPND) of \[18F\]-altanserin measured voxel-by-voxel in the whole brain and the evolution of scores BIS11 in TD patients.
Secondary Outcomes
- Correlation coefficients between functional imaging data (fMRI) and scores of impulsivity measured by the Barratt scale (BIS11).(As the analysis requires a complex imaging processing, this outcome measure will be assessed in the year following the acquisition.)
- Correlation coefficients between receptor-specific imaging data (PET) and other clinical/behavioral scores.(As the analysis requires a complex imaging processing, this outcome measure will be assessed in the year following the acquisition.)
- Correlation coefficients between functional imaging data (fMRI) and other clinical/behavioral scores.(As the analysis requires a complex imaging processing, this outcome measure will be assessed in the year following the acquisition.)